Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 178Lung Neoplasms 60Neoplasms 24Neoplasm Metastasis 17Parkinson Disease 4, Autosomal Dominant Lewy Body 13Mesothelioma, Malignant 12Carcinoma 11Colorectal Neoplasms 10Mesothelioma 9Meningeal Carcinomatosis 8Melanoma 7Brain Neoplasms 7Adenocarcinoma of Lung 7Pancreatic Neoplasms 6Advanced Solid Tumors 5Uterine Cervical Neoplasms 4Ovarian Neoplasms 4Neoplasms by Site 4Colonic Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Non-squamous Non-small Cell Lung Cancer 3Neoplasms by Histologic Type 3NSCLC 3Lung Diseases 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Bronchogenic 3Adenocarcinoma 3Thoracic Neoplasms 2

Interventions

Paclitaxel 2Cisplatin 2Carboplatin 2osimertinib 1cemiplimab 1Surgical Procedures, Operative 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Non-small Cell Lung Cancer × Pemetrexed × 1 year × Clear all
NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡